Close menu

November 24th, 2022 | 12:40 CET

New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

  • Mining
  • Commodities
  • Biotechnology
  • chemicals
Photo credits:

As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BASF SE NA O.N. | DE000BASF111 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , Manuka Resources Limited | AU0000090292

Table of contents:

    Manuka Ressources: Facing a revaluation due to vanadium project?

    Manuka Ressources is certainly not known to many investors in this country. But the gold and silver producer is worth a look. Why? For one, Manuka has two projects - Wonawinta Silver and Mt Boppy Gold - that are already in production. They are now the largest silver producer in Australia. In the last fiscal year (ended June 30), Manuka generated revenue of AUD 53.5 million and a positive operating cash flow of AUD 8.9 million. There should be new data on Mt Boppy in the first quarter of 2023. On this basis, a decision on a production expansion will be made later in the year.

    In addition to the profitable operating business, Manuka took advantage of an opportunity in the summer of 2022 and secured an exciting project in New Zealand: the South Taranaki Bight project (STB project). This project is a VTM (vanadium-titanium-magnetite) iron sands project. It is said to have a resource potential of 3.8 billion tons. A preliminary feasibility study is already available, and the potential annual vanadium production is estimated at 55 million pounds. This could make it the world's third-largest vanadium producer after China and Russia. Vanadium is a relatively unknown metal, but all the more important. Among other things, it is needed for batteries and is, therefore, an important element for the energy transition. It is, therefore, not surprising that it is counted among the critical raw materials by the US, the EU and Australia. On the stock market - the share is also traded in Frankfurt - Manuka is currently valued at AUD 72 million. That is not too much, given the Company's profitable core business and the importance of vanadium. Those interested should note December 7, 2022, in their calendars. The Company will then present at the 5th IIF online investor conference. Participation is free for interested investors (click here to register

    BioNTech: Newsflow in sight

    With a market capitalization of EUR 38 billion, BioNTech naturally plays in a different league. But for the German biotech star, things have been anything but good on the stock market this year. From EUR 212 at the start of the year, the share price fell to EUR 123 within a few weeks. Since then, the share price has moved sideways with significant upward and downward fluctuations. Since the end of October, the mood has improved considerably, and the share is again trading above EUR 150. The reason: investors are increasingly focusing on the development pipeline of the Mainz-based company. And this is full to bursting.

    Thanks to the billions in profits from the COVID-19 vaccine, the Mainz-based company can go full throttle with development, especially in cancer research. The pipeline currently comprises 19 product candidates in 24 ongoing clinical trials. Accordingly, there should be a tidy newsflow at the Mainz-based company in the coming year. BioNTech, for example, has announced new data from up to 10 clinical trials for 2023.

    And, of course, there is the ongoing revenue from the COVID-19 vaccine - even if it is declining. In the current year, revenue is expected to be in the range of EUR 16 to 17 billion. At the end of the third quarter, BioNTech already had a bulging treasury. The Company had EUR 13.4 billion in cash and cash equivalents. In addition, a large part of the EUR 7.3 billion in trade receivables outstanding at the reporting date had already been received. As a result, the Company is fully financed for the coming years. To put this in perspective: in the current year, costs for research, sales/administration and capital expenditures total a maximum of EUR 2.6 billion.

    BASF: Analysts cautious

    Fundamentally, BASF is currently favorably valued. Despite the turmoil on the energy market, the DAX-listed group performed better than analysts expected in the third quarter. Sales rose by 12% to EUR 21.9 billion. EBIT (after special items) of EUR 1.29 billion was down on the prior-year quarter (Q3 2021: EUR 1.82 billion), but the profit is still decent. EBIT (before special items) of between EUR 6.8 billion and EUR 7.2 billion is forecast for fiscal 2022. If the worst-case scenario with blackout and long winter does not materialize, BASF, with a market capitalization of EUR 45 billion, is anything but expensive. However, the share price has also risen by over 30% within a few weeks.

    Therefore, analysts are currently cautious. Only yesterday, Baader Bank warned against write-downs. In the analysts' view, the high inventory levels and poor economic outlook will likely lead to high write-downs in the chemical sector. Should BASF have to close parts of its Ludwigshafen plant temporarily, high write-downs would be unavoidable. Jefferies is also cautious. The analysts rate BASF shares as "hold" with a price target of EUR 49. They, too, fear that the current quarter will be challenging in the chemical industry.

    Stock market analysts are hoping for a good year in 2023. Numerous study results are pending at BioNTech. If these turn out to be predominantly positive, further increases in the share price are likely. 2023 will also be important for Manuka Resources. In the first months of 2023, there will be news about the gold project. In addition, vanadium will come more and more into focus. BASF is more dependent on external factors such as the gas price and the global economy.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Stefan Feulner on March 20th, 2023 | 09:37 CET

    Evotec, Defence Therapeutics, Morphosys - Movement in the biotech sector

    • Biotechnology
    • Investments

    Is a new wave of takeovers starting in the biotech sector? Already last year, acquisitions by Big Pharma were expected to increase, but these largely failed to materialize. However, this could accelerate in the current year. On the one hand, pharmaceutical companies, such as vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio; on the other hand, second-tier stocks are attractive targets due to the strong correction.


    Commented by Nico Popp on March 20th, 2023 | 08:00 CET

    BYD, Defense Metals, JinkoSolar - Energy transition reloaded! This is what matters now

    • Mining
    • RareEarths
    • Electromobility
    • Solar

    If you order a new photovoltaic system today, you cannot avoid products from China. Even German brands often work with Chinese partners and benefit from local technology at favorable prices. But the energy transition is facing a turning point: The gap between East and West is getting deeper and deeper. We look at what this means for companies in the sector and where opportunities could arise.


    Commented by Nico Popp on March 16th, 2023 | 11:57 CET

    Interest roller coaster! This is how you profit! K+S, Saturn Oil + Gas, Deutsche Telekom

    • Mining
    • Oil
    • Inflation
    • fertilizer
    • Telecoms

    Interest rates will remain high for longer - that was the expectation last week. After two bank failures, interest rate expectations have recently collapsed. Some investors in the USA are expecting the first interest rate cuts as early as June. Whether these scenarios are set in stone and what they mean for investors - we provide an analysis using three stocks as examples.